Oncoinvent to present Radspherin Phase 2 ovarian cancer trial at ESMO 2026

Oncoinvent said a trial-in-progress abstract for its Phase 2 randomized intraperitoneal radium-224 therapy in ovarian cancer is scheduled for ESMO 2026 in Madrid on Oct. 24. Separate Radspherin manufacturing and dosimetry work is due at EANM 2026 in Vienna on Oct. 19.